While some Big Pharma companies can fairly be accused of being too
passive in dealing with upcoming patent expirations and relying too much
on cost-cutting to boost numbers, that's not really the case for
Bristol-Myers Squibb (BMY).
Not only has Bristol-Myers continued to invest in the clinic, but the
company has also been an active acquirer in the biotech space. Although
Bristol-Myers has respectable growth prospects relative to its peer
group, this earnings stream seems fairly valued today.
Read the full article here:
Bristol-Myers No Bargain
No comments:
Post a Comment